For the second therapy-relevant biomarker of gastric carcinoma, Her2/neu, a minimum of five tumor-bearing biopsies is also required for reasons of heterogeneous distribution of Her2/neu within the tumor. The gene discussed is ERBB2; the disease is gastric carcinoma.